When will Galenica report earnings and why does it matter for GALE.SW stock?

Galenica reports Q1 earnings on 10 Mar 2026. The update matters because management guidance, pharmacy same-store sales, and Logistics contracts drive near-term revenue and margin expectations for GALE.SW stock.

What is Meyka AI's short-term forecast for GALE.SW stock?

Meyka AI's forecast model projects **CHF 110.34** in 12 months for GALE.SW stock, implying about **16.44%** upside from **CHF 94.75**. This is a model projection, not a guarantee.

What valuation metrics should investors check in the GALE.SW stock report?

Key metrics are **PE 24.33**, **P/S 1.16**, **P/B 3.24**, dividend yield **2.45%**, and free cash flow per share **CHF 5.98**. These help assess value and dividend sustainability for GALE.SW stock.

What operational risks could hit GALE.SW stock after earnings?

Risks include weaker pharmacy traffic, margin contraction in Products & Care, slower Logistics volumes, and net debt to EBITDA near **2.34**, which could constrain capital allocation and pressure GALE.SW stock.

CH Stocks

GALE.SW Galenica AG (SIX) Q1 earnings 10 Mar 2026: margins and guidance in focus

ByDanny Kontos March 10, 2026

GALE.SW stock trades at CHF 94.75 as Galenica AG prepares to report Q1 results on 10 Mar 2026 intraday. Investors will focus on margins, pharmacy sales and Logistics & IT trends. The group shows EPS CHF 3.86 and PE 24.33, with market cap at CHF 4,678,757,272.00. We track guidance, same-store pharmacy sales, and cash flow versus expectations.